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Sir,
In 2008, the alarming level of antibiotic resistance in France led
us to release regional guidelines for the treatment of urinary
tract infections (UTIs).1 Briefly, we recommended (i) the avoid-
ance of fluoroquinolones for uncomplicated UTIs and (ii) the
use of fosfomycin (single 3 g dose) or nitrofurantoin (100 mg
three times a day, 5 days) as first-line treatment. Accordingly,
fosfomycin and nitrofurantoin prescriptions increased, while
fluoroquinolone prescriptions declined.2 In February 2011, the
French Agency for the Safety of Medicine and Health Products
(ANSM) published a drug monitoring alert concerning nitrofuran-
toin.3 This letter reported new cases of severe hepatic and
pulmonary toxicity after prolonged treatments with nitrofuran-
toin. National guidelines were suspended, while nitrofurantoin’s
use as prophylaxis for UTIs was strongly discouraged. One year
later the ANSM issued its new guidelines, stating that: (i) nitrofur-
antoin is responsible for severe pulmonary and hepatic toxicity;
(ii) nitrofurantoin should be used for documented cystitis due
to susceptible microorganisms only when no other antimicrobial
presenting a better benefit/risk ratio can be used orally; (iii) nitro-
furantoin can nevertheless be considered for empirical treat-
ment in cases of urgency or in the setting of a previous history
of multidrug-resistant bacteria; and (iv) nitrofurantoin must
not be used as prophylaxis.
We assessed the impact of the ANSM guidelines on drugs
prescribed for UTIs in our region using antibiotic prescription
data (nitrofurantoin, fosfomycin and fluoroquinolones with
the exception of anti-pneumococcal fluoroquinolones) extracted
from the region’s health insurance agency (ambulatory care
for women aged 15–65 years). Antibiotic consumption was
measured from May 2007 to August 2012 via monthly
totals of daily defined doses (DDDs) according to WHO
recommendations.4
The publication of the drug monitoring alert led to a prompt and
significant (P,0.001) decrease in nitrofurantoin use: the relative
variation was 249.3% 16 months after the release (Figure 1). We
also observed a significant increase in 3 day fluoroquinolone treat-
ment packs (lomefloxacin), single-dose fluoroquinolone packs
(ofloxacin or ciprofloxacin) and multi-dose ofloxacin packs.
Throughout the entire study period, the consumption of fosfomy-
cin increased, that of ciprofloxacin was stable and that of norfloxa-
cin decreased, with no change in trend (Figure 1). Our dataset
did not allow the tracing of indications for nitrofurantoin prescrip-
tions (i.e. short-term use versus prophylaxis or intermittent use).
However, a French global prescription survey suggests that 75%
of nitrofurantoin is prescribed for short-term treatments.5 It is
thus very likely that the two-to-one reduction in nitrofurantoin
use in our region is not only linked to the ban on nitrofurantoin
for UTI prophylaxis but has also impacted short-term use. For the
latter, prescribers largely replaced nitrofurantoin with fluoroquino-
lones.
The alert was the consequence of a survey of nitrofurantoin’s
adverse effects: the French Committee on Drug Monitoring
reported severe adverse effects, mainly pulmonary or hepatic,
with a frequency of 12.7 per year (1 per 20551 nitrofurantoin pre-
scriptions).5 This frequency increased with treatment duration:
from 1 case per 24800 short-term prescriptions (,1 month) to
1 case per 7666 long-term prescriptions (.1 month). In addition,
the context of this alert must be taken into account. It was
issued shortly after the French medical community had been
rocked by the Mediator scandal, which appeared to some to
expose the French pharmaceutical oversight apparatus as relative-
ly permissive, if not lax.6
To our knowledge, no other European country has released
similar recommendations, while most of them use more nitrofur-
antoin than France, including for recurrent UTIs.7 According to
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most European experts’ analyses, there is no strong scientific evi-
dence to limit the use of nitrofurantoin for both incident and recur-
rent short-term UTI treatment, and its use is now recommended in
numerous guidelines worldwide.8 The incidence of serious adverse
events due to antibiotic classes deserves scrutiny. A survey led by
the CDC estimated nearly identical incidence rates in emergency
department visits triggered by nitrofurantoin and quinolone use
(9.8 versus 9.2 visits per 10000 outpatient prescriptions, respect-
ively); the study aggregated data for short- and long-term nitrofur-
antoin therapy.9
From our point of view, the unfortunate phrasing of new French
guidelines left virtually no room for nitrofurantoin in UTIs, given
that cultures are not routinely collected and thus true infection is
rarely documented in women presenting with symptoms of UTI.
In conclusion, while long-term, prophylactic nitrofurantoin
should be restricted, we believe that nitrofurantoin should retain
its place in the therapeutic armamentarium for UTIs, especially
in the face of rising multidrug-resistant Enterobacteriaceae. The
tremendous impact of increased fluoroquinolone consumption
on antimicrobial resistance has been well documented.10 In the
setting of rapidly increasing antimicrobial resistance and an
alarming paucity of novel therapeutic options, it is imperative
that policy makers avoid reactionary measures and take instead
the long view.
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Figure 1. Graphical representation of the segmented regression modification of antibiotic use before and after the release of the ANSM alert. FQs,
fluoroquinolones.
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Sir,
Chronic kidney disease (CKD) is an emerging clinical issue in HIV,
particularly in ageing infected patients. Nephrotoxicity is a major
issue and a frequent cause of drug switching owing to glomerular
or tubular damage and the fear of progressive CKD.1,2However, the
incidence and impact of urolithiasis as an independent contributor
to CKD are not known in HIV-infected patients.
Historically, antiretroviral-induced urolithiasis has been common
inpatientstreatedwith indinavir,probablyduetodrugcrystallization
and precipitation in the kidneys.3
At present, with regards to the risk of urolithiasis, the use of
boosted or unboosted atazanavir as preferred protease inhibitor
(PI) is of concern. In a large retrospective study of 1240
HIV-infected individuals, Hamada et al.4 reported a urolithiasis
incidence of 23.7 cases per 1000 patient-years among atazanavir-
treated patients. Notably, the authors postulated that atazanavir/
ritonavir can promote kidney stones via similar mechanisms to
indinavir-induced urolithiasis.4 This single-centre study,4 as the
authors pointed out, had several limitations owing to its observa-
tional and retrospective nature and because of the absence of
renal stone composition analyses. In particular, the hypothesized
pathogenetic mechanism – atazanavir-supersaturated urine
inducing crystalluria – is difficult to test in consideration of the
lack of association between serum bilirubin levels, surrogate
markers of plasma atazanavir concentration and the risk of
kidney stones.
By contrast, baseline data showed significantly higher uric acid
concentrations in patients treated with atazanavir/ritonavir com-
pared with patients treated with other PIs. Even though uric acid
levels did not affect the Cox proportional hazard regression model
results, and atazanavir/ritonavir exposure was associated with a
10-fold increased risk for kidney stones, these results may have
been distorted by a ‘channelling’ bias. Atazanavir/ritonavir is prefer-
entially prescribed to patients with higher metabolic risk profiles
(European AIDS Clinical Society; Version 6.1; November 2012; http://
www.europeanaidsclinicalsociety.org/index.php?option¼com_con
tent&view¼article&id¼59&Itemid=41).
An expanding body of evidence supports the notion that kidney
stones are not always a separate entity but in some instances re-
present an epiphenomenon of a systemic metabolic disorder,
being associated with insulin resistance and metabolic syn-
drome.5,6In keeping with the study by Hamadaetal.,4 it is plausible
that at least some of the reported effects of atazanavir/ritonavir
could be confounded by physician prescription.
Interestingly, the prevalence of nephrolithiasis seems higher
among HIV-infected individuals than the general population
(0.8%).2 Raheem et al.7 described 46 cases of nephrolithiasis in a
cohort of 436 HIV-positive subjects, corresponding to an overall
11% prevalence: similar to what is expected in the general popula-
tion. Unfortunately, stone analysis was only available in seven sub-
jects and documented four cases of calcium oxalate monohydrate
crystals and only one case each of cystine, uric acid and atazanavir
crystals. A similar prevalence of kidney stones was described in the
Castle study, the largest randomized clinical trial on atazanavir/ri-
tonavir ever performed in naive patients.3
Though evidence in HIV-infected individuals is far from being
conclusive, the study by Hamadaetal.4 suggests a thorough meta-
bolic evaluation for nephrolithiasis in HIV-infected patients with re-
current episodes of kidneystones, a family historyof nephrolithiasis
or evidence of multiple kidney stones at imaging.
However, we suggest caution in interpreting the epidemiologic-
al data linking atazanavir exposure and kidney stones owing to a
potential ‘channelling’ bias. Indeed, an excess number of patients
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